GEMINA LABS ANNOUNCES APPOINTMENT OF SENIOR SCIENTIFIC ADVISER

November 18, 2021

GEMINA LABORATORIES LTD. 

News Release 

November 18, 2021 

GEMINA LABS ANNOUNCES APPOINTMENT OF SENIOR SCIENTIFIC ADVISER 

November 18, 2021, Vancouver, British Columbia: Gemina Laboratories Ltd. (CSE: GLAB) (FRA:8I7) (the  “Company” or “Gemina”) is pleased to announce the appointment of Professor Michael Catt as Senior  Scientific Adviser to the Company. 

Professor Catt is an expert in in-vitro diagnostic development for human health and wellbeing. In a storied  career, he has held senior development roles at some of the world’s leading in-vitro diagnostic and human  wellness companies. While at Unilever, Professor Catt served as Head of Research for Women’s Health at  Unipath and was a co-originator of novel consumer health and wellbeing products marketed under the 

Clearblue and Clearplan brands, now part of Swiss Precision Diagnostics. Subsequent roles with both  multinational and diverse technology start-ups have similarly led to further contributions to novel health  and wellbeing products and services. Professor Catt co-created Unilever’s ‘Healthy Ageing’ programme,  directly leading to his appointment as a Professor of Practice at the Institute for Ageing and Health,  Newcastle University and his subsequent contribution to the establishment of the UK’s new National  Innovation Centre for Ageing, serving as Director and as Co-Principal Investigator for the UK National  Institute of Health Research Innovation Observatory. Professor Catt is now Emeritus Professor at  Newcastle University Population Health Sciences Institute and holds a prestigious Turing fellowship. 

Gemina began working with Professor Catt in November 2020, at which time Professor Catt, in support of  Paragreen Associates, undertook a technical review of the Company’s surface chemistry platform. After  the conclusion of that review process, Professor Catt continued to work with Gemina on an advisory basis  - a role that has already proved immensely productive, as the Company has evolved successive generations of its platform.  

“The Company is immensely fortunate to work with someone of Mike’s stature,” stated Rob Greene,  Gemina’s co-founder and CTO. “Mike brings to Gemina his internationally significant expertise in the rapid  testing domain, and a global network of potential partners in academia, industry and government. It’s fair  to say that Mike could devote his talents to any number of opportunities, so it is with great pleasure that  we’re able to formalise his role within Gemina. It is very exciting looking forward to what we will  accomplish working together.” 

In conjunction with the appointment, pursuant to the Company’s stock option plan, Gemina has granted  options to acquire 100,000 common shares of the Company, at an exercise price of $0.45 cents per  common share exercisable for a term of 5 years from the date of grant, subject to vesting requirements. 

On Behalf of the Board of Directors 

John Davies 

CEO 

Gemina Laboratories Ltd.

About Gemina Laboratories Ltd. 

Gemina Labs is a biosensor and diagnostic company with a transformative, patented, proprietary  chemistry that powers next-generation testing platforms for a wide range of pathogens that affect human health and wellness. Our technology drives testing platforms that are fast, affordable and accurate, and  easily self-administered. Our development pipeline includes platforms for the rapid testing of COVID-19,  influenza and other viruses. Additional information on the Company can be found at  www.geminalabs.com. 

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined  in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy  of this Release. 

Forward Looking Statements 

This news release includes forward-looking information and statements, which may include, but are not  limited to, information and statements regarding or inferring the future business, operations, financial  performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company.  Such statements include statements regarding the anticipated terms of any proposed transaction or 

engagement. Information and statements which are not purely historical fact are forward-looking  statements. Forward-looking information and statements involve and are subject to assumptions and  known and unknown risks, uncertainties, and other factors which may cause actual events, results,  performance, or achievements of the Company to be materially different from future events, results,  performance, and achievements expressed or implied by forward-looking information and statements  herein. Although the Company believes that any forward-looking information and statements herein are  reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such  information and statements, there can be no assurance that any such forward-looking information and  statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation  of such risks and uncertainties and should not place undue reliance upon such forward-looking  information and statements. Furthermore, the Company is presently unable to fully quantify the impact  that the Covid-19 pandemic will have on its operations and recognizes that certain eventualities may  affect planned or assumed performance moving forward. As such, any forward-looking information and  statements herein are made as of the date hereof, and except as required by applicable laws, the  Company assumes no obligation and disclaims any intention to update or revise any forward-looking  information and statements herein or to update the reasons that actual events or results could or do differ  from those projected in any forward looking information and statements herein, whether as a result of  new information, future events or results, or otherwise, except as required by applicable laws.  

For more information regrading the Company, please contact: 

James Tansey 

Telephone: 604-562-4546  

Email: investor@geminalabs.com

Receive Company Updates
Thank you. Your submission has been received and you will now receive company updates via email.
Oops! Something went wrong while submitting the form.

Press and Updates

AGM DOCUMENTATION

December 20, 2022
Read More

GEMINA LABS APPOINTS DR MICHAEL SHANNON AS CHAIR OF CLINICAL ADVISORY BOARD

December 20, 2022
Read More

GEMINA LABS ANNOUNCES RESEARCH COLLABORATION ON NEXT GENERATION BIOSENSORS

December 19, 2022
Read More

Enter Your Email To Sign Up For Campaign Updates. 

Thank you. Your submission has been received and you will now receive company updates via email.
Oops! Something went wrong while submitting the form.